RCOG issues guidelines for nausea and vomiting in pregnancy

RCOG issues guidelines for nausea and vomiting in pregnancy

June 29 2016 New guidance for healthcare professionals to support pregnant women experiencing...

New measures promote red flag warnings to help prevent maternal deaths

New measures promote red flag warnings to help prevent maternal deaths

June 29 2016 New resources to help doctors assess unwell pregnant or post-partum women, and to...

‘Physical Activity and Lifestyle’ to join RCGP clinical priorities

‘Physical Activity and Lifestyle’ to join RCGP clinical priorities

June 29 2016 The Royal College of General Practitioners has launched its latest clinical priority...

More needs to be done to reduce antibacterial prescribing, says Public Health Wales

More needs to be done to reduce antibacterial prescribing, says Public Health Wales

June 29 2016 There has been an overall reduction of 5.1% in total antibacterial usage in primary...

Bronchioloitis guidance will help reduce antibiotic prescribing, says RCGP

Bronchioloitis guidance will help reduce antibiotic prescribing, says RCGP

June 27 2016 NICE guidance on bronchiolitis in children will help reassure parents and help...

  • RCOG issues guidelines for nausea and vomiting in pregnancy

    RCOG issues guidelines for nausea and vomiting in pregnancy

    Wednesday, 29 June 2016 11:10
  • New measures promote red flag warnings to help prevent maternal deaths

    New measures promote red flag warnings to help prevent maternal deaths

    Wednesday, 29 June 2016 10:57
  • ‘Physical Activity and Lifestyle’ to join RCGP clinical priorities

    ‘Physical Activity and Lifestyle’ to join RCGP clinical priorities

    Wednesday, 29 June 2016 10:53
  • More needs to be done to reduce antibacterial prescribing, says Public Health Wales

    More needs to be done to reduce antibacterial prescribing, says Public Health Wales

    Wednesday, 29 June 2016 10:48
  • Bronchioloitis guidance will help reduce antibiotic prescribing, says RCGP

    Bronchioloitis guidance will help reduce antibiotic prescribing, says RCGP

    Tuesday, 28 June 2016 13:25

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

June 29 2016 New guidance for healthcare professionals to support pregnant women experiencing nausea and vomiting and hyperemesis gravidum have been published.
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...